280 filings
Page 2 of 14
8-K
mafrm 7l0pqqt2
26 Jun 23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
6:03am
8-K
3he4 7c336f
15 Jun 23
Departure of Directors or Certain Officers
4:56pm
DEFA14A
we2d7sy gzfsm9
25 May 23
Additional proxy soliciting materials
4:39pm
8-K
vzhnlxkjanfry
9 May 23
Esperion Reports First Quarter 2023 Financial Results
7:22am
8-K
2a0z00u
4 May 23
Other Events
9:26am
ARS
5g29xjefm
13 Apr 23
Annual report to shareholders
4:08pm
8-K
o9osb9lepeu61g
27 Mar 23
Other Events
4:49pm
8-K
psjmfcmeodl71 hqme
22 Mar 23
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:40pm
424B3
phie3g6
22 Mar 23
Prospectus supplement
4:35pm
424B5
fhurb
21 Mar 23
Prospectus supplement for primary offering
4:06pm
8-K
k094vxhn3yyr61
15 Mar 23
Other Events
4:24pm
8-K
rpev13wbd
10 Mar 23
Regulation FD Disclosure
4:31pm
8-K
bogr5kf seq0
6 Mar 23
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin
6:04am
424B5
z5lhor57rjmi89w
21 Feb 23
Prospectus supplement for primary offering
4:07pm
8-K
xwv7gt5umchdcje7k9
21 Feb 23
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
7:30am
8-K
6yzqgk
9 Jan 23
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
9:04am